SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- November 10, 2006 -- Novacea, Inc. (NASDAQ: NOVC) today announced that researchers presented updated Phase 1 data of AQ4N (banoxantrone), an investigational drug designed to target the hypoxic regions present in most solid tumors, at the 18th EORTC-NCI-AACR Symposium on November 9, 2006. The conference -- “Molecular Targets and Cancer Therapeutics Symposium” -- is organized by the European Organization for Research and Treatment of Cancer (EORTC) in conjunction with the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), and is being held in Prague, November 7-10, 2006.
